<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320629</url>
  </required_header>
  <id_info>
    <org_study_id>HRA-E01</org_study_id>
    <nct_id>NCT03320629</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive
      apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal
      squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>evaluated in 24 months since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the first day of treatment to death or last survival confirm date，up to 24 months</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>tumor assessment every 6 weeks ，up to 24 month</time_frame>
    <description>Baseline to measured progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>tumor assessment every 6 weeks，up to 24 months</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>evaluated in the 24th month since the treatment began according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</time_frame>
    <description>throughout study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Refractory or Metastatic Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>apatinib and S-1 radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>apatinib S-1 radiotherapy</intervention_name>
    <description>apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>apatinib and S-1 radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>S-1 radiotherapy</intervention_name>
    <description>S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>S-1 radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age:18 to 70 years old (man or female); 2. Imageology diagnosed with refractory or
             metastatic esophageal squamous cell carcinoma(pathologically diagnosed with
             supraclavicular lymph node metastasis and anastomotic recurrence ); 3. The distant
             metastatic is oligotransfera, with radiotherapy indication; 4. Patients with
             measurable lesions(measuring≥10mm on spiral CT scan, satisfying the criteria in
             RECIST1.1); 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 6.
             Major organ function has to meet the following certeria:

               1. For results of blood routine test (without blood transfusion within 14 days)

                    1. HB≥100g/L;

                    2. ANC≥3.0×109/L;

                    3. PLT≥100×109/L;

               2. For results of blood biochemical test：

                    1. TBIL&lt;1.5×ULN；

                    2. ALT and AST&lt;2.5×ULN, but&lt; 5×ULN if the transferanse elevation is due to
                       liver metastases；

                    3. Serum creatinine ≤1ULN , calculated creatinine clearance＞50 ml/min(per the
                       Cockcroft-Gault formula); 7. Life expectancy greater than or equal to 3
                       months; 8. Women of childbearing age must have contraceptive measures or
                       have test pregnancy (serum or urine) enroll the study before 7 days, and the
                       results must be negative, and take the methods of contraception during the
                       test and the last to have drugs after 8 weeks. Men must be contraception or
                       has sterilization surgery during the test and the last to have drugs after 8
                       weeks; 9. Coagulation function is normal, without active hemorrhage and
                       thrombosis:

                    1. INR&lt;1.5×ULN

                    2. APTT&lt;1.5×ULN

                    3. PT&lt;1.5ULN 10. Participants were willing to join in this study, and written
                       informed consent; 11. Participants were good adherence, cooperate with the
                       follow-up.

        Exclusion Criteria:

          -  1. Allergic to apatinib; 2. Have high blood pressure and antihypertensive drug
             treatment can not control (systolic blood pressure &gt; 140 mmHg, diastolic blood
             pressure &gt; 90 mmHg), with classⅡand above coronary heart disease and arrhythmia
             (including QTc lengthened men &gt; 450 ms, women &gt; 470 ms) and cardiac insufficiency; 3.
             A variety of factors influencing oral drugs (such as unable to swallow, nausea,
             vomiting, chronic diarrhea and intestinal obstruction, etc.); 4. Patients with
             tendency of gastrointestinal bleeding, including the following;

               1. Active ulcerative lesions, and defecate occult blood (+ +);

               2. Has melena and hematemesis in three months;

               3. For defecate occult blood (+) or(+/-) ,must be received gastroscopy, the
                  physicians consider there are potential bleeding risk with ulcers, hemorrhagic
                  diseases; 5. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with
                  bleeding tendency; 6. Patients with thrombosis or anticoagulant drug therapy; 7.
                  Patients with symptoms of central nervous system metastasis; Patients with other
                  malignant tumors within 5 years (except for the treated skin basal cell carcinoma
                  and cervical carcinoma in situ); 8. history of psychiatric drugs abuse and can't
                  quit or patients with mental disorders; 9. Less than 4 weeks from the last
                  clinical trial; 10. Have received prior treatment with anti- VEGF/VEGFR; 11.
                  Researchers considered there are serious harm to patient safety or affect the
                  patients who have completed the study; 12. Pregnant or lactating women; 13. The
                  researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Wang</last_name>
    <phone>13931182128</phone>
    <email>wangjunzr@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang</last_name>
      <phone>13931182128</phone>
      <email>wangjunzr@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Jun wang</investigator_full_name>
    <investigator_title>Director of radiotherapy department1</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

